Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
Sponsor: Wasuchon Chaichan
Summary
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.
Official title: Efficacy and Safety of Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis: A Double-Blind Randomized Placebo-Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-06-15
Completion Date
2028-10
Last Updated
2026-06-05
Healthy Volunteers
No
Conditions
Interventions
Pentoxifylline 400 mg Oral Tablet
Pentoxifylline 400 mg capsule will be taken orally twice daily after meals, once in the morning and once in the evening, for 12 weeks. The intervention will be given as add-on therapy while participants continue standard topical treatment for plaque psoriasis.
Placebo
Matching placebo capsule will be taken orally twice daily after meals, once in the morning and once in the evening, for 12 weeks. The placebo will be given as add-on therapy while participants continue standard topical treatment for plaque psoriasis.
Locations (1)
University of Phayao Hospital
Phayao, Changwat Phayao, Thailand